| ORIGINAL ARTICLE |
|
| Year : 2021 | Volume
: 33
| Issue : 1 | Page : 1-5 |
|
|
The expression level of aspartate beta-hydroxylase (ASPH) and clinical importance in acute myeloid leukemia
Fadwa Said1, Amro M El Ghammaz2, Mohamed A Shazly2, Mohamed O Azzazi2
1 Department of Clinical Pathology, Faculty of Medicine, Cairo University, Giza, Egypt
2 Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Correspondence Address:
Fadwa Said
MD, Department of Clinical Pathology, Professor of Clinical and Chemical Pathology, Cairo University 11562
Egypt
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ejolm.ejolm_2_22
|
|
|
Background
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors in the bone marrow and peripheral blood. Aspartate β-hydroxylase (ASPH) is a membrane protein that promotes cellular motion. Recent studies have revealed that ASPH is an indicator of carcinoma in humans and is highly expressed in AML.
Patients and methods
The study included 30 AML patients diagnosed and classified by complete blood count with differential, bone marrow study, flow cytometric, cytogenetic, and molecular studies, and 10 normal participants of the same age group. The serum level of ASPH was measured in both cases and controls by enzyme-linked immunosorbent assay.
Results
The level of ASPH was significantly higher in patients than in controls (P < 0.001). Patients with mutant FLT3 had higher serum ASPH compared with those with wild FLT3 with a trend toward statistical significance (P = 0.074). Other clinical and laboratory variables had no relationship with ASPH levels in the blood.
Conclusion
This study detected a significant increase in ASPH levels in the blood of AML patients more than the controls, shedding the light on the role of ASPH in AML genesis and paving the way for the development of new medications that block ASPH's leukemogenesis effect in the future.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
